Goldman Sachs
ATNM icon

Goldman Sachs’s Actinium Pharmaceuticals ATNM Stock Holding History

Goldman Sachs’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.9K Sell
70,241
-117
-0.2% -$139 ﹤0.01% 6257
2025
Q4 		$95.7K Buy
+70,358
New +$103K ﹤0.01% 6193
2025
Q3 		– Sell
-91,411
Closed -$128K – 6325
2025
Q2 		$128K Buy
91,411
+14,600
+19% +$21.9K ﹤0.01% 5766
2025
Q1 		$124K Sell
76,811
-58,485
-43% -$74.2K ﹤0.01% 5745
2024
Q4 		$170K Buy
135,296
+43,903
+48% +$68.1K ﹤0.01% 5683
2024
Q3 		$172K Buy
91,393
+51,115
+127% +$202K ﹤0.01% 5498
2024
Q2 		$298K Buy
40,278
+29,131
+261% +$240K ﹤0.01% 5110
2024
Q1 		$87.3K Sell
11,147
-4,333
-28% -$27.9K ﹤0.01% 5264
2023
Q4 		$78.6K Sell
15,480
-30,864
-67% -$159K ﹤0.01% 5331
2023
Q3 		$274K Buy
46,344
+32,405
+232% +$216K ﹤0.01% 4932
2023
Q2 		$103K Sell
13,939
-79,176
-85% -$674K ﹤0.01% 5351
2023
Q1 		$880K Buy
93,115
+83,025
+823% +$876K ﹤0.01% 4472
2022
Q4 		$107K Buy
10,090
+35
+0.3% +$355 ﹤0.01% 5464
2022
Q3 		$74K Buy
+10,055
New +$62.5K ﹤0.01% 5746
2018
Q2 		– Sell
-981
Closed -$11K – 5652
2018
Q1 		$11K Buy
+981
New +$16.7K ﹤0.01% 5734
2015
Q4 		– Sell
-3,178
Closed -$169K – 7130
2015
Q3 		$169K Sell
3,178
-1,440
-31% -$96.2K ﹤0.01% 6122
2015
Q2 		$367K Buy
+4,618
New +$394K ﹤0.01% 5523

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's ATNM Position: Q1 2026 in Review

Goldman Sachs reduced its Actinium Pharmaceuticals (ATNM) stake by 0.17% in Q1 2026, selling an estimated $139 and leaving 70,241 shares worth $69.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6257.

Goldman Sachs first reported a position in ATNM in Q2 2015 and has held it in 17 quarters since. The position peaked at $880K in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Goldman Sachs held 70,241 shares of Actinium Pharmaceuticals worth $69.9K as of Q1 2026.
  • Goldman Sachs sold 117 Actinium Pharmaceuticals shares in Q1 2026, an estimated $139.
  • Actinium Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6257 holding.
  • Goldman Sachs first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 17 quarters since.
  • Goldman Sachs's Actinium Pharmaceuticals position peaked at $880K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.